Amplia Therapeutics Ltd Asset Resilience Ratio

Latest as of September 2025: 65.46%

Amplia Therapeutics Ltd asset resilience ratio. Amplia Therapeutics Ltd (ATX) has an Asset Resilience Ratio of 65.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Amplia Therapeutics Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$29.16 Million
≈ $20.63 Million USD Cash + Short-term Investments

Total Assets

AU$44.54 Million
≈ $31.52 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Amplia Therapeutics Ltd (2017–2025)

Asset resilience ratio of Amplia Therapeutics Ltd from 2017 to 2025. This chart shows how Amplia Therapeutics Ltd's Asset Resilience Ratio has changed over time. Read Amplia Therapeutics Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Amplia Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Amplia Therapeutics Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$29.16 Million 65.46%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$29.16 Million 65.46%

Asset Resilience Insights

  • Very High Liquidity: Amplia Therapeutics Ltd maintains exceptional liquid asset reserves at 65.46% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Amplia Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Amplia Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Amplia Therapeutics Ltd Asset Resilience Ratio by Year (2017–2025)

Amplia Therapeutics Ltd asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Amplia Therapeutics Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 47.36% AU$10.86 Million
≈ $7.69 Million
AU$22.94 Million
≈ $16.23 Million
+24.56pp
2024-03-31 22.80% AU$3.39 Million
≈ $2.40 Million
AU$14.85 Million
≈ $10.50 Million
-19.92pp
2023-03-31 42.73% AU$7.98 Million
≈ $5.65 Million
AU$18.68 Million
≈ $13.22 Million
-0.67pp
2022-03-31 43.39% AU$10.62 Million
≈ $7.52 Million
AU$24.48 Million
≈ $17.32 Million
+26.40pp
2021-03-31 16.99% AU$1.85 Million
≈ $1.31 Million
AU$10.88 Million
≈ $7.70 Million
+4.84pp
2020-03-31 12.16% AU$1.11 Million
≈ $784.07K
AU$9.12 Million
≈ $6.45 Million
-1.35pp
2019-03-31 13.50% AU$1.24 Million
≈ $878.02K
AU$9.19 Million
≈ $6.50 Million
-59.61pp
2018-03-31 73.11% AU$1.93 Million
≈ $1.37 Million
AU$2.64 Million
≈ $1.87 Million
+10.17pp
2017-03-31 62.94% AU$4.74 Million
≈ $3.36 Million
AU$7.54 Million
≈ $5.33 Million
--
pp = percentage points

About Amplia Therapeutics Ltd

AU:ATX Australia Biotechnology
Market Cap
$32.32 Million
AU$45.68 Million AUD
Market Cap Rank
#23310 Global
#851 in Australia
Share Price
AU$0.09
Change (1 day)
+5.95%
52-Week Range
AU$0.08 - AU$0.27
All Time High
AU$16.20
About

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develo… Read more